Targeting EGFR and VEGFR-2 Kinases With Nanoparticles: A Computational Approach for Cancer Therapy Advancement

References

• Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458(7239):719–724. doi:10.1038/nature07943.
   PubMed Web of Science ®Google Scholar
• Podlaha O, Riester M, De S, Michor F. Evolution of the cancer genome. Trends Genet. 2012;28(4):155–163. doi:10.1016/j.tig.2012.01.003.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–821. doi:10.1038/s41423-020-0488-6.
   PubMed Web of Science ®Google Scholar
• Yip HYK, Papa A. Signaling pathways in cancer: therapeutic targets, combinatorial treatments, and new developments. Cells. 2021;10(3):659. doi:10.3390/cells10030659.
   PubMed Web of Science ®Google Scholar
• Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020;12(1):8. doi:10.1186/s13073-019-0703-1.
   PubMed Web of Science ®Google Scholar
• Zengin M, Unsal Tan O, Arafa RK, Balkan A. Design and synthesis of new 2-oxoquinoxalinyl-1,2,4-triazoles as antitumor VEGFR-2 inhibitors. Bioorg Chem. 2022;121:105696. doi:10.1016/j.bioorg.2022.105696.
   PubMed Web of Science ®Google Scholar
• Mourad AAE, Farouk NA, El-Sayed E-SH, Mahdy ARE. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives. Life Sci. 2021;277:119531. doi:10.1016/j.lfs.2021.119531.
   PubMed Web of Science ®Google Scholar
• McKenzie S, Kyprianou N. Apoptosis evasion: The role of survival pathways in prostate cancer progression and therapeutic resistance. J Cell Biochem. 2006;97(1):18–32. doi:10.1002/jcb.20634.
   PubMed Web of Science ®Google Scholar
• Regad T. Targeting RTK signaling pathways in cancer. Cancers (Basel). 2015;7(3):1758–1784. doi:10.3390/cancers7030860.
   PubMed Web of Science ®Google Scholar
• Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol. 2007;19(2):117–123. doi:10.1016/j.ceb.2007.02.010.
   PubMed Web of Science ®Google Scholar
• Le X, Nilsson M, Goldman J, Reck M, Nakagawa K, Kato T, et al. Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. J Thorac Oncol. 2021;16(2):205–215. doi:10.1016/j.jtho.2020.10.006.
   PubMed Web of Science ®Google Scholar
• Chen F, Chen N, Yu Y, Cui J. Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) inhibitors plus antiangiogenic agents as first-line treatments for patients with advanced EGFR-mutated non-small cell lung cancer: a meta-analysis. Front Oncol. 2020;10:904. doi:10.3389/fonc.2020.00904.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676. doi:10.1038/nm0603-669.
   PubMed Web of Science ®Google Scholar
• Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G. Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med. 2014;2(12):123. doi:10.3978/j.issn.2305-5839.2014.08.14.
   PubMedGoogle Scholar
• Niu G, Chen X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets. 2010;11(8):1000–1017. doi:10.2174/138945010791591395.
   PubMed Web of Science ®Google Scholar
• Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res. 2001;23(2–3):263–272. doi:10.1385/IR:23:2-3:263.
   PubMed Web of Science ®Google Scholar
• Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9(5):9. doi:10.3390/cancers9050052.
   PubMed Web of Science ®Google Scholar
• Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012;136(2):331–345. doi:10.1007/s10549-012-2289-9.
   PubMed Web of Science ®Google Scholar
• Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117–1134. doi:10.1016/j.cell.2010.06.011.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246. doi:10.1016/S1470-2045(11)70393-X.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307. doi:10.1038/nature10144.
   PubMed Web of Science ®Google Scholar
• Falcon BL, Chintharlapalli S, Uhlik MT, Pytowski B. Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents. Pharmacol Ther. 2016;164:204–225. doi:10.1016/j.pharmthera.2016.06.001.
   PubMed Web of Science ®Google Scholar
• Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV. Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy. Clin Cancer Res. 2023;29(1):30–39. doi:10.1158/1078-0432.CCR-22-1366.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li Y, Wang Y, Lin C, Zhang D, Chen J, et al. Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy. J Hematol Oncol. 2022;15(1):89. doi:10.1186/s13045-022-01310-7.
   PubMed Web of Science ®Google Scholar
• Elia SG, Al‐Karmalawy AA, Nasr MY, Elshal MF. Loperamide potentiates doxorubicin sensitivity in triple‐negative breast cancer cells by targeting MDR1 and JNK and suppressing mTOR and Bcl‐2: In vitro and molecular docking study. J Biochem Mol Toxicol. 2022;36(1):e22938. doi:10.1002/jbt.22938.
   PubMed Web of Science ®Google Scholar
• El-Naggar AM, Hassan AMA, Elkaeed EB, Alesawy MS, Al‐Karmalawy AA. Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2. Bioorg Chem. 2022;123:105770. doi:10.1016/j.bioorg.2022.105770.
   PubMed Web of Science ®Google Scholar
• Niedermaier T, Gredner T, Kuznia S, Schöttker B, Mons U, Brenner H. Vitamin D supplementation to the older adult population in Germany has the cost‐saving potential of preventing almost 30 000 cancer deaths per year. Mol Oncol. 2021;15(8):1986–1994. doi:10.1002/1878-0261.12924.
   PubMed Web of Science ®Google Scholar
• Le Y, Gan Y, Fu Y, Liu J, Li W, Zou X, et al. Design, synthesis and in vitro biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment. J Enzyme Inhib Med Chem. 2020;35(1):555–564. doi:10.1080/14756366.2020.1715389.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Johnson JR, Chen Y-F, Sridhara R, Pazdur R. FDA drug approval summary: Erlotinib (Tarceva®) tablets. Oncologist. 2005;10(7):461–466. doi:10.1634/theoncologist.10-7-461.
   PubMed Web of Science ®Google Scholar
• Choi H-J, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev. 2015;34(1):19–40. doi:10.1007/s10555-014-9538-9.
   PubMed Web of Science ®Google Scholar
• El‐Helby AA, Sakr H, Eissa IH, Al‐Karmalawy AA, El‐Adl K. Benzoxazole/benzothiazole‐derived VEGFR‐2 inhibitors: design, synthesis, molecular docking, and anticancer evaluations. Arch Pharm (Weinheim). 2019;352(12):e1900178. doi:10.1002/ardp.201900178.
   PubMed Web of Science ®Google Scholar
• Amin DN, Bielenberg DR, Lifshits E, Heymach JV, Klagsbrun M. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc Res. 2008;76(1):15–22. doi:10.1016/j.mvr.2008.01.002.
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Faivre S, Raymond E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat Rev. 2008;34(1):37–48. doi:10.1016/j.ctrv.2007.09.003.
   PubMed Web of Science ®Google Scholar
• Wells SA, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28(5):767–772. doi:10.1200/JCO.2009.23.6604.
   PubMed Web of Science ®Google Scholar
• Najahi-Missaoui W, Arnold RD, Cummings BS. Safe nanoparticles: are we there yet? Int J Mol Sci. 2020;22(1):385. doi:10.3390/ijms22010385.
   PubMed Web of Science ®Google Scholar
• Sharma S, Parveen R, Chatterji BP. Toxicology of nanoparticles in drug delivery. Curr Pathobiol Rep. 2021;9(4):133–144. doi:10.1007/s40139-021-00227-z.
   PubMedGoogle Scholar
• Usui T, Ban HS, Kawada J, Hirokawa T, Nakamura H. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening. Bioorg Med Chem Lett. 2008;18(1):285–288. doi:10.1016/j.bmcl.2007.10.084.
   PubMed Web of Science ®Google Scholar
• Sanphanya K, Wattanapitayakul SK, Phowichit S, Fokin VV, Vajragupta O. Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach. Bioorg Med Chem Lett. 2013;23(10):2962–2967. doi:10.1016/j.bmcl.2013.03.042.
   PubMed Web of Science ®Google Scholar
• Downs RT, Hall-Wallace M. The American Mineralogist crystal structure database. Am Mineral. 2003;88:247–250.
   Web of Science ®Google Scholar
• Ghoorah AW, Devignes M-D, Smaïl-Tabbone M, Ritchie DW. Protein docking using case-based reasoning. Proteins Struct Funct Bioinf. 2013;81(12):2150–2158. doi:10.1002/prot.24433.
   PubMed Web of Science ®Google Scholar
• Ritchie DW, Venkatraman V. Ultra-fast FFT protein docking on graphics processors. Bioinformatics. 2010;26(19):2398–2405. doi:10.1093/bioinformatics/btq444.
   PubMed Web of Science ®Google Scholar
• Macindoe G, Mavridis L, Venkatraman V, Devignes M-D, Ritchie DW. HexServer: an FFT-based protein docking server powered by graphics processors. Nucleic Acids Res. 2010;38(Web Server issue):W445–9. doi:10.1093/nar/gkq311.
   PubMed Web of Science ®Google Scholar
• Ritchie DW. Evaluation of protein docking predictions using Hex 3.1 in CAPRI rounds 1 and 2. Proteins. 2003;52(1):98–106. doi:10.1002/prot.10379.
   PubMed Web of Science ®Google Scholar
• Ritchie DW, Grudinin S. Spherical polar Fourier assembly of protein complexes with arbitrary point group symmetry. J Appl Crystallogr. 2016;49(1):158–167. doi:10.1107/S1600576715022931.
   Google Scholar
• Ritchie DW, Kozakov D, Vajda S. Accelerating and focusing protein–protein docking correlations using multi-dimensional rotational FFT generating functions. Bioinformatics. 2008;24(17):1865–1873. doi:10.1093/bioinformatics/btn334.
   PubMed Web of Science ®Google Scholar
• Mustard D, Ritchie DW. Docking essential dynamics eigenstructures. Proteins Struct Funct Bioinf. 2005;60(2):269–274. doi:10.1002/prot.20569.
   PubMed Web of Science ®Google Scholar
• Ritchie DW, Kemp GJ. Protein docking using spherical polar Fourier correlations. Proteins. 2000;39(2):178–194. doi:10.1002/(SICI)1097-0134(20000501)39:2<178::AID-PROT8>3.0.CO;2-6.
   PubMed Web of Science ®Google Scholar
• Delano WL. The PyMOL molecular graphics system. CCP4 Newsl Protein Crystallogr. 2002;40:82–92.
   Google Scholar
• Wang X, Bove AM, Simone G, Ma B. Molecular bases of VEGFR-2-mediated physiological function and pathological role. Front Cell Dev Biol. 2020;8:599281. doi:10.3389/fcell.2020.599281.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol. 2021;14(1):85. doi:10.1186/s13045-021-01096-0.
   PubMed Web of Science ®Google Scholar
• Jafari E, Khajouei MR, Hassanzadeh F, Hakimelahi GH, Khodarahmi GA. Quinazolinone and quinazoline derivatives: recent structures with potent antimicrobial and cytotoxic activities. Res Pharm Sci. 2016;11(1):1–14.
   PubMedGoogle Scholar